Fingolimod (FTY) induces a re-modulation of the immune system. Lymphocytes subsets may predict Multiple Sclerosis disease activity in FTY patients. Immune system re-modulation can be a biomarker of FTY therapeutic response. ROC curves stratified patients for the risk of relapse at T6 and Gd + lesions at T12.